Meningococcal disease and vaccination in North America

Journal of Paediatrics and Child Health

Volumn 37, Issue 5 SUPPL., 2001, Pages 20-27

  Pollard, A J ^a,b   Scheifele, D ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Epidemiology; Meningococcocus; Neisseria meningitidis; Vaccines

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE PROTEIN CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

BACTERIAL VIRULENCE; BACTERIUM; CANADA; COLLEGE STUDENT; CONFERENCE PAPER; DRUG EFFICACY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION RISK; MENINGOCOCCOSIS; MORTALITY; NORTH AMERICA; PRIORITY JOURNAL; UNITED KINGDOM; VACCINATION; WINTER;

EID: 0034772213     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.2001.00679.x     Document Type: Conference Paper

References (69)

1. Deaths: Final data for 1997
2. Surveillance of invasive meningococcal disease in Canada, 1995-96
3. The changing epidemiology of meningococcal disease in the United States, 1992-96
4. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population
5. The Neisseriae
6. Global epidemiology of meningococcal disease
7. Neisseria meningitidis
8. Canadian communicable disease surveillance system. Disease specific case definitions and surveillance methods
9. Case definitions for infectious conditions under public health surveillance
10. Meningococcal disease in Canada: Surveillance summary to 1987
11. Notifiable diseases: Summary of reported cases per 100 000 population, United States
12. Summary of notifiable diseases, United States, 1993
13. Meningococcal disease in Belgium. Secondary attack rate among household, daycare nursery and pre-elementary school contacts
14. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis
15. Influenza A and meningococcal disease
16. Smoking, the environment and meningococcal disease: A case control study
17. Tobacco smoke as a risk factor for meningococcal disease
18. Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health
19. Maternal cigarette smoking and invasive meningococcal disease: A cohort study among young children in metropolitan Atlanta, 1989-96
20. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak
21. Outbreak of serogroup C meningococcal disease associated with campus bar patronage
22. Disco fever: Epidemic meningococcal disease in northeastern Argentina associated with disco patronage
23. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency
24. Complement deficiency states and meningococcal disease
25. Meningococcemia caused by serogroup W135. Association with hypogammaglobulinemia
26. Gamma-M deficiency predisposing to meningococcal septicaemia
27. Complications of splenectomy. Etiology, prevention and management
28. Increased risk of neisserial infections in systemic lupus erythematosus
29. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience
30. Complications and sequelae of meningococcal infections in children
31. Prevention and control of meningococcal disease
32. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia: United States, 2000
33. Serogroup C meningococcal outbreaks in the United States. An emerging threat
34. Control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks
35. Epidemic serogroup B meningococcal disease in Oregon. The evolving epidemiology of the ET-5 strain
36. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada
37. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis
38. Meningococcal disease in Canada and serogroup distribution
39. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood
40. Guidelines for control of meningococcal disease
41. Meningococcal vaccine
42. Meningococcal disease prevention and control strategies for practice-based physicians
43. Statement on meningococcal vaccination for travellers
44. Change in recommendation for meningococcal vaccine for travelers
45. Risk of meningococcal infection in college students
46. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis
47. Meningococcal disease falls in vaccine recipients
48. Preclinical studies on a group Y meningococcal conjugate vaccine
49. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States
50. Invasive pneumococcal infections in Canadian children, 1991-98. Implications for new vaccination strategies
51. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
52. Advisory committee on immunization practices vaccines for children programme
53. New opportunities for prevention of meningococcal disease
54. Efficacy of Heamophilus influenzae type b conjugate vaccine PRP-T
55. Meningococcal conjugate vaccines. New opportunities and new challenges
56. Immunologic response of man to group B meningococcal polysaccharide vaccines
57. Vaccines for prevention of meningococcal disease
58. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491
59. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58
60. Provisional cases of selected notifiable disease preventable by vaccination, United States week ending January 2, 1999
61. Meningococcal disease in Canada. Surveillance summary to 1987
62. Which pneumococcal serogroups cause the most invasive disease. Implications for conjugate vaccine formulation and use, part I